Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis

Thrombosis and Haemostasis

Volumn 97, Issue 2, 2007, Pages 181-185

  De Bruijne, Emile L E ^a   Murad, Sarwa Darwish ^a   De Maat, Moniek P M ^a   Tanck, Michael W T ^b   Haagsma, Elizabeth B ^c   Van Hoek, Bart ^d   Rosendaal, Frits R ^d   Janssen, Harry L A ^a   Leebeek, Frank W G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Budd Chiari syndrome; Fibrinolysis; Inflammation; Portal vein thrombosis; Single nucleotide polymorphism; Splanchnic vein thrombosis; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

ADENINE; ALANINE; ANTICOAGULANT AGENT; GUANINE; ISOLEUCINE; THREONINE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THYMINE;

ADULT; AGED; ARTICLE; BUDD CHIARI SYNDROME; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VEIN THROMBOSIS; ADOLESCENT; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; LIVER VEIN THROMBOSIS; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PORTAL VEIN; RISK;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEPATIC VEIN THROMBOSIS; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PORTAL VEIN; RISK FACTORS; THREONINE; VARIATION (GENETICS); VENOUS THROMBOSIS;

EID: 33947545374     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-07-0407     Document Type: Article

References (28)

1. Janssen HL, Garcia-Pagan JC, Elias E, et al. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003; 38: 364-371.
2. Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J Hepatol 2000; 32: 865-871.
3. Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study Blood 2000; 96: 2364-2368.
4. Mahmoud AE, Elias E, Beauchamp N, et al. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997; 40: 798-800.
5. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-14484.
6. Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commum 1989; 162: 933-939.
7. Hendriks D, Wang W, Scharpe S, et al. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034: 86-92.
8. Eaton DL, Malloy BE, Tsai SP, et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-21838.
9. Plow EF, Allampallam K, Redlitz A. The plasma carboxypeptidases and the regulation of the plasminogen system. Trends Cardiovasc Med 1997; 7: 71-75.
10. Wang W, Boffa MB, Bajzar L, et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-27181.
11. van Tilburg NE, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-2859.
12. Libourel EJ, Bank I, Memardi JR, et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 2002; 87: 1068-1073.
13. Eichinger S, Schonauer V, Weltermann A, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103: 3773-3776.
14. Martini CH, Brandts A, de Bruijne EL, et al. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 2006; 134: 92-94.
15. Frere C, Tregouet DA, Morange PE, et al. Fine mapping of quantitative trait nucleotides underlying thrombin activatable fibrinolysis inhibitor antigen levels by a trans-ethnic study. Blood 2006; 108: 1562-1568.
16. Brouwers GJ, Vos HL, Leebeek FW, et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001; 98: 1992-1993.
17. Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-2058.
18. Brouwers GJ, Leebeek FW, Tanck MW, et al. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost 2003; 90: 92-100.
19. Epstein MP, Satten GA. Inference on haplotype effects in case-control studies using unphased genotype data. Am J Hum Genet 2003; 73: 1316-1329.
20. Lake SL, Lyon H, Tantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003; 55: 56-65.
21. Schaid DJ, Rowland CM, Tines DE, et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434.
22. Juhan-Vague I, Morange PE, Aubert H, et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002; 22: 867-873.
23. Leebeek FW, Goor MP, Guimaraes AH, et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 3: 2211-2218.
24. Amitrano L, Guardascione MA, Ames PR, et al. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol 2003; 72: 75-81.
25. De Stefano V, Teofili L, Leone G. Acquired and inherited risk factors for splanchnic venous thrombosis. Blood 2001; 97: 3314-3315.
26. Guimaraes AH, Bertina RM, Rijken DC. A new functional assay of thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2005; 3: 1284-1292.
27. Schneider M, Boffa M, Stewart R, et al. Two naturally occurring variants of TAFI (Thr-325 and IIe-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 1021-1030.
28. Murad SD, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39: 500-508.